Choosing the wrong dose is the most common formulation mistake with shatavari. A 200 mg capsule of whole root powder delivers less than 10 mg of active saponins — roughly 20× below the clinical threshold. This guide gives you the evidence-based dose for every indication, the conversion math between standardised extract and whole powder, and the formulation decisions that turn a good concept into a product that actually works.
Quick-Reference Dosage Table
The table below summarises the validated dosage ranges for Shatavari root extract standardised to 40% saponins. These figures are drawn from published clinical studies and traditional Ayurvedic dosimetry. Whole root powder figures are calculated from an 8:1 concentration equivalence ratio.
| Indication | Standardised 40% Extract | Equivalent Whole Powder | Duration |
|---|---|---|---|
| Galactagogue / Lactation support | 500 mg twice daily (1,000 mg/day) |
4,000–8,000 mg/day | 2–8 weeks post-partum |
| Menopausal symptom relief | 500 mg twice daily (1,000 mg/day) |
4,000–8,000 mg/day | 8–12 weeks minimum |
| Hormonal balance / PCOS support | 250–500 mg twice daily (500–1,000 mg/day) |
2,000–4,000 mg/day | 12+ weeks |
| Adaptogenic / General tonic | 250 mg twice daily (500 mg/day) |
2,000–3,000 mg/day | Ongoing / cyclical |
| Gut health / IBS support | 250–500 mg once daily (250–500 mg/day) |
1,500–3,000 mg/day | 4–8 weeks |
| Antioxidant / Immune support | 200–300 mg once daily (200–300 mg/day) |
1,000–2,000 mg/day | Ongoing |
| Combination formula (with Ashwagandha) | 250–500 mg shatavari + 250–500 mg ashwagandha per serving |
— | 8–12 weeks |
Formulator's note: For a 2-capsule serving at 600 mg fill weight (300 mg/cap), a single standardised 40% extract dose of 250 mg covers the adaptogenic/tonic range. To hit the 500 mg therapeutic dose, use a 4-capsule serving or increase capsule size to 500 mg fill. Soft gels at 500–600 mg fill are the most efficient single-capsule delivery vehicle for shatavari.
Standardised Extract vs Whole Root Powder: What It Means for Your Formula
Shatavari root powder naturally contains 2–5% steroidal saponins (Shatavarins I–IX). A 40% saponin-standardised extract concentrates these actives 8–20× relative to the raw root, depending on starting material quality. This has direct consequences for your product label claims, capsule count, and cost-per-dose calculations.
| Parameter | Whole Root Powder | Standardised 40% Extract |
|---|---|---|
| Saponin content | 2–5% | 40% (guaranteed min.) |
| Daily dose to hit 400 mg saponins | 8,000–20,000 mg | 1,000 mg |
| Capsules needed (at 500 mg fill) | 16–40 capsules | 2 capsules |
| Cost-per-dose efficiency | Low | High |
| Label claim: standardised to X% | Not possible | ✓ Yes |
| Batch-to-batch consistency (CoA) | Variable | Consistent (UV-Vis tested) |
| Colour in capsule | Off-white to beige | Light brown powder |
| Taste / Smell | Mild, starchy | Slightly bitter, earthy |
| Moisture content | Up to 12% | Max 5% (spec-controlled) |
For any product making a hormone-balance, lactation, or menopausal claim, standardised extract is the only defensible form. Whole root powder can be used in traditional Ayurvedic multi-herb formulations where the combined herbal matrix is the product rather than a specific active.
Dosage by Indication — Clinical Evidence
1. Lactation Support (Galactagogue)
Shatavari is the best-evidenced herbal galactagogue in Ayurvedic medicine. The key mechanism is saponin-driven modulation of prolactin secretion via dopaminergic pathways. A randomised controlled trial (Sharma et al., The Journal of Social Health and Diabetes) found that mothers taking 500 mg shatavari extract twice daily for 30 days showed a 33% increase in milk output versus placebo. Effect size is dose-dependent — 250 mg/day showed no significant difference from placebo in this study, confirming the 500 mg/serving threshold.
Recommended label dose: 500 mg standardised extract (40% saponins) twice daily with meals. Suitable for use from day 2 post-delivery through 8 weeks. Note: shatavari is generally regarded as safe during lactation; however, as with all botanicals, formulation should include a physician-consult note for nursing mothers.
2. Menopausal Symptom Relief
Shatavari's phytoestrogenic Shatavarins bind weakly to oestrogen receptors (ERα and ERβ) in a tissue-selective manner — acting as agonists in oestrogen-deficient tissue (e.g., vaginal mucosa, bone) and as mild antagonists where oestrogen is excessive. This SERM-like mechanism makes shatavari one of the safer phytoestrogenic herbs for perimenopausal and postmenopausal formulations.
Clinical dosing for menopause: 500 mg extract twice daily (1,000 mg/day). Studies consistently show reduction in vasomotor symptoms (hot flushes, night sweats) after 6–8 weeks, with peak benefit at 12 weeks. Vaginal dryness improvement is observed earlier — typically 4–6 weeks.
3. Hormonal Balance and PCOS
In PCOS, elevated androgens and insulin resistance disrupt the HPG axis. Shatavari's phytoestrogenic activity gently supports oestrogen signalling without directly suppressing androgens — making it a complementary herb rather than a standalone PCOS treatment. Dosing: 500 mg/day (250 mg twice daily) as part of a multi-herb protocol. Clinical pairing with inositol (myo-inositol) or spearmint extract is well-studied.
4. Adaptogenic and General Tonic Use
As a classical Ayurvedic Rasayana (rejuvenating tonic), shatavari is used at lower doses for long-term wellness support. For adaptogenic products, 250 mg once or twice daily of the 40% extract is appropriate. This dose range supports antioxidant activity (inhibition of lipid peroxidation, SOD-like activity) and immune modulation without the higher cost-of-goods of therapeutic dosing.
Source Shatavari Extract for Your Formula
SV Botanica supplies Asparagus racemosus root extract standardised to 40% saponins — CoA on request, samples available in 100g and 500g quantities.
Formulation Tips for Supplement Developers
Capsule Sizing and Fill Weight
The most practical delivery format for a standalone shatavari supplement is a size 00 hard-shell capsule (700 mg fill weight) or a size 0 capsule (500 mg fill). For a 2-capsule serving delivering 1,000 mg/day of 40% extract, a size 0 two-piece capsule at 500 mg fill is ideal. HPMC (vegetarian) shells are preferred for this ingredient since the target demographic (women's health, lactation) skews towards vegetarian consumers.
Compatibility and Excipients
Shatavari extract powder is hygroscopic. Include a desiccant in the bottle and use moisture-resistant packaging. For direct compression tablets, magnesium stearate (1%) and microcrystalline cellulose work well. For soft gels, shatavari extract can be dispersed in medium-chain triglyceride (MCT) oil at a 1:3 (extract:MCT) ratio — absorption is improved with the lipid carrier, potentially allowing a 20–30% dose reduction.
Taste Masking
At 40% saponin concentration, shatavari has a mild bitter-earthy taste that is acceptable in capsules but noticeable in powder blends. For gummies or powder sachets, include a sweetener (stevia or thaumatin at 0.1–0.2%) and a complementary flavour note — vanilla, cardamom, or ashwagandha latte flavours work well given the Ayurvedic positioning.
Combination Strategies
| Formula Concept | Shatavari Dose | Pair With | Target Indication |
|---|---|---|---|
| Women's adaptogen blend | 250–500 mg | Ashwagandha 300–500 mg | Stress, mood, hormonal resilience |
| Lactation support formula | 500 mg | Fenugreek seed 500 mg + Moringa leaf 250 mg | Milk production, postpartum nutrition |
| Menopause support | 500 mg | Black cohosh 40 mg + Sage leaf 300 mg | Vasomotor symptoms, mood |
| PCOS / cycle regulation | 250 mg | Myo-inositol 2,000 mg + Spearmint 900 mg | Androgen balance, insulin sensitivity |
| Gut health tonic | 250 mg | Licorice root 150 mg + Slippery elm 200 mg | Mucosa support, IBS, gut motility |
Safety, Contraindications and Upper Dose Limits
Shatavari has an excellent long-term safety profile. In the traditional Ayurvedic system it is classified as a tridoshic Rasayana — safe for extended use across all constitutional types. Toxicology studies in rats and mice show no adverse effects at doses up to 1,600 mg/kg/day (far exceeding any human supplement dose). No hepatotoxicity, nephrotoxicity, or genotoxicity has been reported in peer-reviewed literature.
Contraindications to state on product labels: (1) Oestrogen-receptor-positive (ER+) breast cancer — the phytoestrogenic activity of Shatavarins is a theoretical risk in ER+ malignancy; consult oncologist before use. (2) Asparagus allergy — rare but documented; cross-reactivity with asparagus vegetable. (3) Diuretic medications — shatavari has mild diuretic activity; potential additive effect with pharmaceutical diuretics. (4) Pregnancy — while used historically in traditional medicine, insufficient human clinical data exists to recommend standardised extract in pregnancy; consult physician.
Upper Dose Limits
| Parameter | Value | Basis |
|---|---|---|
| Maximum studied safe dose (standardised 40%) | 2,000 mg/day | Short-term human studies |
| Traditional maximum (whole powder) | 10,000 mg/day (10g) | Charaka Samhita / Ayurvedic texts |
| Recommended upper dose for supplements | 1,000–2,000 mg/day (40% ext.) | Conservative clinical range |
| No-observed-adverse-effect level (rat, 90-day) | 1,600 mg/kg/day | Preclinical toxicology |
| Safety category (EU) | Traditional herbal medicine | THMPD registration pathway |
| GRAS status (USA) | Not formally listed (dietary supplement) | DSHEA classification |
On-Set Time and Product Claim Guidance
Shatavari is not a fast-acting botanical. Its benefits accumulate over weeks of consistent use. Understanding the timeline helps you set accurate label claims and consumer expectations:
- Week 1–2: Antioxidant enzymes begin to increase; gut mucosa protection begins.
- Week 2–4: Prolactin modulation becomes measurable (lactation products); initial reduction in menopausal hot flushes.
- Week 4–8: Full hormonal support effects; improvement in vaginal hydration and lubrication; sleep quality improvement in menopausal subjects.
- Week 8–12: Peak clinical benefit for hormonal and menopausal indications; sustained cortisol normalisation when combined with ashwagandha.
Label claim guidance: "Results typically experienced after 4–6 weeks of consistent use" is well-supported by available clinical data and is appropriate for general wellness positioning. For a lactation product you can say "noticeable results from 2–3 weeks." Avoid "immediate" or "fast-acting" language — it is not consistent with the mechanism.
For further context on how shatavari compares to ashwagandha when formulating for women's health, see our in-depth comparison: Shatavari vs Ashwagandha for Women's Health. For a full breakdown of grades, standardisation methods, and regulatory documentation, visit the Shatavari Extract Buyer's Guide.
Frequently Asked Questions
For standardised shatavari extract (40% saponins), the clinically validated dose is 250–500 mg per serving, typically taken twice daily, giving a daily total of 500–1,000 mg. This is equivalent to 4,000–8,000 mg of whole shatavari root powder (assuming an 8:1 concentration ratio). The correct dose depends on the indication — lactation support and menopausal symptom relief typically need the higher end (500 mg/serving), while a general adaptogenic or tonic formulation can use 250 mg/serving.
Clinical studies on shatavari for lactation (galactagogue effect) have used 500 mg of a standardised extract twice daily (1,000 mg/day total). The saponin-driven prolactin-modulating effect requires a minimum of 500 mg/day of a 40%-standardised extract to produce a measurable response. Whole root powder studies have used 3,000–6,000 mg/day. For a dedicated lactation supplement, 500 mg standardised extract per serving is the recommended anchor dose.
Whole shatavari root powder contains approximately 2–5% saponins naturally, which means you need 3,000–10,000 mg/day of whole powder to deliver the same saponin load as 500–1,000 mg/day of a 40%-standardised extract. For capsule or tablet formulations with typical fill weights of 400–700 mg, standardised extract is far more practical — it delivers 10–20× more active saponins per gram.
Shatavari (Asparagus racemosus) has an excellent safety profile. In traditional Ayurvedic practice it is used at high doses (up to 10g/day as whole root powder) without adverse events. For standardised 40% extracts, doses up to 2,000 mg/day (1,000 mg twice daily) are considered safe for long-term use. The primary contraindication is oestrogen-receptor-positive (ER+) breast cancer. No hepatotoxicity has been reported in any human or animal study to date.
Most clinical studies report measurable outcomes after 4–8 weeks of consistent use. Galactagogue effects (increased milk production) appear within 2–4 weeks. Menopausal symptom relief is typically observed after 6–8 weeks. Adaptogenic and antioxidant benefits follow a similar timeline. For supplement product labelling, a "4–6 week consistent use" timeframe is evidence-based and appropriate.
Yes — shatavari combines well with several herbs without pharmacokinetic conflicts. The most validated combination is Shatavari + Ashwagandha (250–500 mg each) for women's hormonal and stress support. Shatavari + Moringa is used for lactation support and postpartum nutrition. Shatavari + Fenugreek seed extract is a common galactagogue combination. The one combination to use with care is Shatavari with diuretic herbs (dandelion, horsetail) at high doses, as both promote fluid excretion.